Esperion Therapeutics earnings were -$51.7M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest ESPR earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$21.3M, down 27.8% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ESPR reported annual earnings of -$51.7M, with -75.3% growth. The next ESPR earnings date is May 5, 2025.
Esperion Therapeutics Earnings Reports & History FAQ
What were Esperion Therapeutics's earnings last quarter?
On ESPR's earnings call on Invalid Date, Esperion Therapeutics (NASDAQ: ESPR) reported Q4 2024 earnings per share (EPS) of -$0.11, up 78% year over year. Total ESPR earnings for the quarter were -$21.32 million. In the same quarter last year, Esperion Therapeutics's earnings per share (EPS) was -$0.50.
The next ESPR earnings call is Invalid Date. Add ESPR to your watchlist to be reminded of Esperion Therapeutics's next earnings date.
What was ESPR's earnings growth in the past year?
As of Esperion Therapeutics's earnings date in Invalid Date, Esperion Therapeutics's earnings has grown year over year. ESPR earnings in the past year totalled -$51.75 million.
Is Esperion Therapeutics profitable or losing money?
As of the last Esperion Therapeutics earnings report, Esperion Therapeutics is currently losing money. Esperion Therapeutics's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$51.75 million, a 75.27% decrease year over year.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.